TY - JOUR
T1 - Polychlorinated biphenyl congeners that increase the glucuronidation and biliary excretion of thyroxine are distinct from the congeners that enhance the serum disappearance of thyroxine
AU - Martin, L. A.
AU - Wilson, D. T.
AU - Reuhl, K. R.
AU - Gallo, M. A.
AU - Klaassen, Curtis D.
PY - 2012/3
Y1 - 2012/3
N2 - Polychlorinated biphenyl (PCB) congeners differentially reduce serum thyroxine (T 4) in rats, but little is known about their ability to affect biliary excretion of T 4. Thus, male Sprague-Dawley rats were orally administered Aroclor-1254, Aroclor-1242 (32 mg/kg per day), PCB-95, PCB-99, PCB-118 (16 mg/kg per day), PCB-126 (40 μg/kg per day), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3.9 μg/kg per day), or corn oil for 7 days. Twenty-four hours after the last dose, [ 125I]T 4 was administered intravenously, and blood, bile, and urine samples were collected for quantifying [ 125I]T 4 and in bile [ 125I]T 4 metabolites. Serum T 4 concentrations were reduced by all treatments, but dramatic reductions occurred in response to Aroclor-1254, PCB-99 [phenobarbital (PB)-type congener], and PCB-118 (mixed-type congener). None of the treatments increased urinary excretion of [ 125I]T 4. Aroclor-1254, PCB-118, TCDD, and PCB-126 (TCDD-type congener) increased biliary excretion of T 4-glucuronide by 850, 756, 710, and 573%, respectively, corresponding to marked induction of hepatic UDP-glucuronosyltransferase (UGT) activity toward T 4. PCB-95 and PCB-99 did not induce UGT activity; therefore, the increased biliary excretion of T 4-glucuronide was related to the affinity of congeners for the aryl hydrocarbon receptor. The disappearance of [ 125I]T 4 from serum was rapid (within 15-min) and was increased by Aroclor-1254, PCB-99 and PCB-118. Thus, reductions in serum T 4 in response to PCBs did not always correspond with UGT activity toward T4 or with increased biliary excretion of T 4-glucuronide. The rapid disappearance of [ 125I]T 4 from the serum of rats treated with PB-like PCBs suggests that increased tissue uptake of T 4 is an additional mechanism by which PCBs may reduce serum T 4.
AB - Polychlorinated biphenyl (PCB) congeners differentially reduce serum thyroxine (T 4) in rats, but little is known about their ability to affect biliary excretion of T 4. Thus, male Sprague-Dawley rats were orally administered Aroclor-1254, Aroclor-1242 (32 mg/kg per day), PCB-95, PCB-99, PCB-118 (16 mg/kg per day), PCB-126 (40 μg/kg per day), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3.9 μg/kg per day), or corn oil for 7 days. Twenty-four hours after the last dose, [ 125I]T 4 was administered intravenously, and blood, bile, and urine samples were collected for quantifying [ 125I]T 4 and in bile [ 125I]T 4 metabolites. Serum T 4 concentrations were reduced by all treatments, but dramatic reductions occurred in response to Aroclor-1254, PCB-99 [phenobarbital (PB)-type congener], and PCB-118 (mixed-type congener). None of the treatments increased urinary excretion of [ 125I]T 4. Aroclor-1254, PCB-118, TCDD, and PCB-126 (TCDD-type congener) increased biliary excretion of T 4-glucuronide by 850, 756, 710, and 573%, respectively, corresponding to marked induction of hepatic UDP-glucuronosyltransferase (UGT) activity toward T 4. PCB-95 and PCB-99 did not induce UGT activity; therefore, the increased biliary excretion of T 4-glucuronide was related to the affinity of congeners for the aryl hydrocarbon receptor. The disappearance of [ 125I]T 4 from serum was rapid (within 15-min) and was increased by Aroclor-1254, PCB-99 and PCB-118. Thus, reductions in serum T 4 in response to PCBs did not always correspond with UGT activity toward T4 or with increased biliary excretion of T 4-glucuronide. The rapid disappearance of [ 125I]T 4 from the serum of rats treated with PB-like PCBs suggests that increased tissue uptake of T 4 is an additional mechanism by which PCBs may reduce serum T 4.
UR - http://www.scopus.com/inward/record.url?scp=84857377134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857377134&partnerID=8YFLogxK
U2 - 10.1124/dmd.111.042796
DO - 10.1124/dmd.111.042796
M3 - Article
C2 - 22187485
SN - 0090-9556
VL - 40
SP - 588
EP - 595
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 3
ER -